|
22 Nov 2022 |
OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for Hair Loss
|
|
22 Nov 2022 |
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
|
|
21 Nov 2022 |
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
|
|
21 Nov 2022 |
Medera receives FDA clearance for a first-in-human gene therapy trial for heart failure with preserved ejection fraction
|
|
18 Nov 2022 |
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
|
|
18 Nov 2022 |
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
|
|
18 Nov 2022 |
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
|
|
17 Nov 2022 |
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
|
|
14 Nov 2022 |
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
|
|
14 Nov 2022 |
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
|
|
12 Nov 2022 |
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis
|
|
12 Nov 2022 |
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
|
|
12 Nov 2022 |
Carisma Therapeutics Announces Clinical & Pre-Clinical Updates
|
|
12 Nov 2022 |
Triumvira Immunologics Announces Updated Data from Ongoing TACTIC 2 Trial of TAC01-HER2 in Patients with HER2 Positive Solid Tumors
|
|
12 Nov 2022 |
Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022
|
|
11 Nov 2022 |
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
|
|
11 Nov 2022 |
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
|
|
10 Nov 2022 |
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
|
|
10 Nov 2022 |
IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022
|
|
10 Nov 2022 |
Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting
|
|
10 Nov 2022 |
Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
|
|
10 Nov 2022 |
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
|
|
10 Nov 2022 |
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
|
|
10 Nov 2022 |
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
|
|
10 Nov 2022 |
KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting
|
